Genelux (Genelux) Debt-to-Equity : 0.13 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Genelux Debt-to-Equity?

Genelux's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.65 Mil. Genelux's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.87 Mil. Genelux's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $19.47 Mil. Genelux's debt to equity for the quarter that ended in Dec. 2023 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Genelux's Debt-to-Equity or its related term are showing as below:

GNLX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.15 Med: -0.75 Max: 0.13
Current: 0.13

During the past 4 years, the highest Debt-to-Equity Ratio of Genelux was 0.13. The lowest was -1.15. And the median was -0.75.

GNLX's Debt-to-Equity is ranked better than
52.85% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs GNLX: 0.13

Genelux Debt-to-Equity Historical Data

The historical data trend for Genelux's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Debt-to-Equity Chart

Genelux Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.15

-0.76

-0.74

0.13

Genelux Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								-0.74	1.34	0.08	0.08	0.13

Competitive Comparison of Genelux's Debt-to-Equity

For the Biotechnology subindustry, Genelux's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genelux's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Genelux's Debt-to-Equity falls into.

Genelux Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Genelux's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.653	+	1.866)	/	19.473
	=	0.13

Genelux's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.653	+	1.866)	/	19.473
	=	0.13

Genelux (NAS:GNLX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Genelux Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Genelux's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genelux (Genelux) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361

Website

https://www.genelux.com

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Executives

Tony Yu	officer: VP, Clinical Trial Operations	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas	director	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay	10 percent owner	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder	officer: General Counsel	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak	officer: Chief Financial Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick	director, officer: President and CEO	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello	officer: VP, Pharmaceutical Development	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson	officer: Chief Financial Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett	officer: Head of Quality	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling	officer: Head of Regulatory	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang	officer: Associate VP, Research	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli	director	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla	officer: Chief Medical Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361